» Articles » PMID: 37623576

Potential Implication of Azole Persistence in the Treatment Failure of Two Haematological Patients Infected with

Overview
Journal J Fungi (Basel)
Date 2023 Aug 25
PMID 37623576
Authors
Affiliations
Soon will be listed here.
Abstract

Invasive aspergillosis (IA) is a major cause of morbidity and mortality in patients receiving allogeneic haematopoieticcell transplantation. The deep immunosuppression and a variety of potential additional complications developed in these patients result in IA reaching mortality rates of around 50-60%. This mortality is even higher when the patients are infected with azole-resistant isolates, demonstrating that, despite the complexity of management, adequate azole treatment can have a beneficial effect. It is therefore paramount to understand the reasons why antifungal treatment of IA infections caused by azole-susceptible isolates is often unsuccessful. In this respect, there are already various factors known to be important for treatment efficacy, for instance the drug concentrations achieved in the blood, which are thus often monitored. We hypothesize that antifungal persistence may be another important factor to consider. In this study we present two case reports of haematological patients who developed proven IA and suffered treatment failure, despite having been infected with susceptible isolates, receiving correct antifungal treatment and reaching therapeutic levels of the azole. Microbiological analysis of the recovered infective isolates showed that the patients were infected with multiple strains, several of which were persisters to voriconazole and/or isavuconazole. Therefore, we propose that azole persistence may have contributed to therapeutic failure in these patients and that this phenomenon should be considered in future studies.

Citing Articles

Aspergillus fumigatus mitogenomes and their influence on azole-resistant and -susceptible populations.

Delbaje E, Pontes L, Rhodes J, Steenwyk J, Lu L, Dos Reis T NPJ Antimicrob Resist. 2025; 3(1):15.

PMID: 40016509 PMC: 11868573. DOI: 10.1038/s44259-025-00083-6.


Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.

Hoenigl M, Arastehfar A, Arendrup M, Bruggemann R, Carvalho A, Chiller T Clin Microbiol Rev. 2024; 37(2):e0007423.

PMID: 38602408 PMC: 11237431. DOI: 10.1128/cmr.00074-23.

References
1.
Wingard J, Ribaud P, Schlamm H, Herbrecht R . Changes in causes of death over time after treatment for invasive aspergillosis. Cancer. 2008; 112(10):2309-12. DOI: 10.1002/cncr.23441. View

2.
Nicolle M, Benet T, Thiebaut A, Bienvenu A, Voirin N, Duclos A . Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica. 2011; 96(11):1685-91. PMC: 3208687. DOI: 10.3324/haematol.2011.044636. View

3.
Gonzalez-Garcia P, Alonso-Sardon M, Rodriguez-Alonso B, Almeida H, Romero-Alegria A, Vega-Rodriguez V . How Has the Aspergillosis Case Fatality Rate Changed over the Last Two Decades in Spain?. J Fungi (Basel). 2022; 8(6). PMC: 9225319. DOI: 10.3390/jof8060576. View

4.
Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll A, Skiada A . ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2016; 102(3):433-444. PMC: 5394968. DOI: 10.3324/haematol.2016.152900. View

5.
Patterson T, Thompson 3rd G, Denning D, Fishman J, Hadley S, Herbrecht R . Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4):e1-e60. PMC: 4967602. DOI: 10.1093/cid/ciw326. View